Drug company Pfizer and BioNTech announced on 9th November that a Phase III study of the SARSCoV-2 vaccine candidate BNT162b2 was more than 90% effective in preventing COVID-19. Details in this week's #COVID19 Science Summary compiled by Dr Andrew Mujugira.